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Patients with acquired immunodeficiency syndrome (AIDS) are often infected with a number of other
heterologous viruses in addition to the initial human immunodeficiency virus (HIV) infection, and these agents
could act as potential reactivating agents of latent HIV. A new antigenically distinct herpesvirus, designated
human herpesvirus 6 (HHV-6), has recently been isolated from patients with AIDS and has been shown to infect
a number of different human cells, specifically human T cells, B cells, and glial cells. Since these are some of
the same cells that harbor the AIDS virus, it is quite important to determine any interaction between this new
herpesvirus and HIV. In this report, we demonstrate that HHV-6 can trans-activate the HIV promoter in
human T-cell lines as measured by the expression of the bacterial gene chloramphenicol acetyltransferase. This
indicates that stimulation of HIV gene expression by HHV-6 could play a role in HIV pathogenesis.
Infection of human helper T lymphocytes by human
immunodeficiency virus (HIV) results in the development of
acquired immunodeficiency syndrome (AIDS), which is
characterized by the severe and persistent breakdown of the
immune system (3, 4, 7). Human herpesviruses are respon-
sible for a significant proportion of the collective morbidity
and mortality reported in patients with AIDS. HIV replica-
tion has been shown only in a small proportion of T cells in
vivo, and virus tends to persist for a prolonged period of time
(3, 9, 20). The sequence of events needed to trigger the
conversion of a persistent latent infection to an acute cy-
tolytic HIV infection is not known. One of these events
could be heterologous viral infections. Of potential major
significance to our understanding of the relationship between
HIV and heterologous viruses has been the in vitro demon-
stration of the activation of the HIV long terminal repeat
(LTR), which contains the viral promoter, by other viruses.
The early gene products of viruses such as herpes simplex
virus type 1 (10), cytomegalovirus (2), and adenovirus (13)
have been found to trans-activate the HIV LTR promoter
activity. Human herpesvirus 6 (HHV-6) is a new herpesvi-
rus, antigenically distinct from other human herpesviruses
and has been isolated recently from the peripheral blood
lymphocytes of patients with AIDS (8, 17), from patients
with lymphoproliferative disorders (15), and from infants
with exanthem subitum (19). It infects human T cells (in-
cluding both T4+ and T8+ cells), B cells, and glioma cells in
vitro. However, the target cell(s) for viral latency is not
known. This study examines the in vitro interaction between
HIV and HHV-6, and this preliminary report presents evi-
dence for the trans-activation of the HIV promoter by
HHV-6.
We used the prototype GS strain of HHV-6 (15). Two
human T-cell lines, HSB-2 (ATCC-CCL 120.1. CCRF-HSB-
2) and HuT-78 (ATCC-TIB 161), grown in RPMI 1640 with
10% serum supplement (CPSR-1; Sigma Chemical Co.),
were used for the propagation of HHV-6. Infection of these
cells with HHV-6 resulted in a characteristic aggregation and
enlargement of infected cells by 3 to 6 days postinfection.
Electron microscopic examination of thin sections of in-
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fected HSB-2 cells revealed large quantities of developing
viral particles in the host cell nucleus as well as complete
enveloped particles in cytoplasmic vacuoles and in the
extracellular compartments (Fig. 1). These viruses exhibit a
characteristic herpesvirus morphology (15), and the whole
virus measured about 160 ,um in diameter. More than 30
virus-specific peptides were detected in these infected cells
(N. Balachandran, R. E. Amelse, W. W. Zhou, and B. R.
Fegley, submitted for publication). To measure the infectiv-
ity, fresh HSB-2 cells (106) were infected with dilutions of
either infected cell supernatant fluids or cell lysates. After 5
days, infected and uninfected cells were washed in phos-
phate-buffered saline, fixed on coverslides by cold acetone,
and tested for the presence of viral antigens with an indirect
immunofluorescence assay using a prestandardized dilution
of a patient's serum (15). After 5 days postinfection, the
culture supernates of HSB-2 cells usually yielded about 104
per ml of infective virus (a 50% tissue culture infective dose).
The yields from HuT cells were usually about fivefold lower
than that of HSB-2 cells.
The human T-cell line, HuT-78, was transfected with a
plasmid that contained the HIV LTR region ligated upstream
of the indicator chloramphenicol acetyltransferase (CAT)
gene (Fig. 2). Construction of the HIV-CAT plasmid has
been described previously (F. Kashanchi and C. Wood,
Proc. Natl. Acad. Sci. USA, in press). The HIV LTR region
of the plasmid contained both the 3' untranslated region and
the repeat sequences. HuT cells were transfected with the
plasmid by protoplast fusion which is described in detail
elsewhere (16). Briefly, bacterial cells that contained the
plasmid were treated with lysozyme to form protoplasts and
were then fused to HuT-78 cells using polyethylene glycol.
After transfection, the cells were cocultured with HHV-
6-infected HuT-78 or HSB-2 cells (4 days postinfection),
culture supernatant fluid from these cells (5 x 104 per ml of
infective virus [a 50% tissue culture infective dose]), or
control uninfected cells. The T cells were collected 2 days
later, and 2 x 106 cells were lysed by sonication. The cell
extracts were assayed for CAT activity as described by
Gorman et al. (5). [14C]chloramphenicol (0.3 ,uCi) was incu-
bated with 0.5 mM acetyl coenzyme A and 3 [I of cell
extract in a final volume of 150 [LI of 0.5 M Tris hydrochlo-
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FIG. 1. Electron micrograph of HHV-6 infected HSB-2 cells on day 6. Thin sections of glutaraldehyde-fixed infected cells were made and
stained with uranyl acetate and lead citrate. Grids were examined under a JEOL-100 CX transmission electron microscope. Enveloped
intracytoplasmic (C) viral particles in vacuoles (V) and extracellular (E) viral particles are shown. Arrow indicates the projections on the viral
envelope.
ride (pH 7.4) for 3 h at 37°C. The radioactive chloramphen-
icol was then extracted with ethyl acetate and analyzed by
thin-layer chromatography in chloroform-methanol (95:5).
The percentage of chloramphenicol converted to acetylated
forms was determined for each sample.
The results of the HIV-LTR-directed CAT gene expres-
sion with or without the addition of HHV-6 are shown in Fig.
3 and Table 1. Little CAT activity was detected in T cells
transfected with HIV-CAT alone (Fig. 3, lane 2). When the
transfected cells were cocultured with uninfected HuT-78 or
HSB-2 cells, there was no significant change in CAT enzy-
matic activity (Fig. 3, lanes 5 and 8). However, when these
T cells were infected with culture supernatant fluids contain-
ing HHV-6 (Fig. 3, lanes 3 and 6) or cocultured with
HHV-6-infected HuT-78 or HSB-2 cells (Fig. 3, lanes 4 and
7), CAT expression was dramatically increased (42- to
66-fold). These data indicate that infection of HIV-CAT-
transfected T cells with HHV-6 trans-activates the HIV-
LTR-directed gene expression. Since our HIV-CAT con-
struct contains the simian virus 40 enhancer (Fig. 2), it is
possible that HHV-6 activates the simian virus 40 enhancer
rather than the HIV promoter itself. A control plasmid that
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FIG. 2. (A) Schematic diagram of the HIV-CAT construct. The
HIV-LTR was ligated to the CAT gene and inserted into the
pSV2neo plasmid. (B) The LTR insert was the XhoI fragment that
contained the untranslated (U3) and repeat sequence (R) regions as
well as a portion of the vector sequence (---).
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FIG. 3. HHV-6 activation of the HIV promoter. A 1-U sample of
CAT enzyme converted 97% of the chloramphenicol substrate to
acetylated forms (arrows) (lane 1). HuT-78 cells were transfected
with HIV-CAT (lane 2) and cocultured with HHV-6 viral stock
grown in HuT-78 cells (lane 3), HHV-6-infected HuT-78 cells (2:1,
respectively) (lane 4), or with uninfected HuT-78 cells (2:1, respec-
tively) (lane 5). HIV-CAT-transfected cells were also incubated with
HHV-6 viral stock grown in the HSB-2 T-cell line (lane 6), cocul-
tured with HSB-2 infected cells (2:1) (lane 7), or cocultured with
uninfected HSB-2 cells (2:1) (lane 8). Lysates from untransfected
HuT-78 did not contain detectable CAT activity (lane 9).
lacked the simian virus 40 enhancer also showed similar
trans-activating activity (66- and 71-fold) in the presence of
HHV-6 (data not shown), confirming the observation that
HHV-6 acts on the HIV promoter rather than on the simian
virus 40 enhancer. Table 1 summarizes the average percent
acetylation of chloramphenicol from several experiments.
This trans-activating effect seems to be dependent on the
amount of HHV-6 used to infect the transiently transfected T
cells. Approximately 31% of HuT cells and 27% of HSB-2
cells expressed viral antigens as measured by an indirect
immunofluorescence assay (data not shown). When trans-
fected cells are cocultured with fewer virus-infected cells
(10:1) the amount of trans-activation is lower (33 x) than that
in a cocultivation with an equal number of transfected and
infected cells (1:1, 59x), demonstrating that this effect is
dose dependent. The CAT activity of T cells that were
cocultured with HHV-6 infected cells was consistently
higher than that of T cells that were infected directly with
virus. With other herpesviruses, viral envelope glycopro-
teins are expressed on the infected cell membrane and
mediate cell-to-cell fusion (14). Such a phenomonon has also
been demonstrated with HHV-6 (1, 15), and the fusion of
infected cells with transfected T cells results in the delivery
of a higher quantity of infective intracellular virus, presyn-
thesized HHV-6 viral proteins, or both. This could explain
the greater trans-activation seen with HHV-6-infected cells
versus HHV-6 alone.
HIV has an endogenous trans-activator protein called tat.
This trans-activator has been characterized as a 14-kilo-
dalton protein that interacts directly or indirectly via cellular
factors with the LTR of HIV to increase the steady-state
level of viral mRNA (12, 18). To determine whether HHV-6
infection has any effect on tat trans-activation, the HuT-78
TABLE 1. trans-Activation of HIV LTR CAT after infection
with HHV-6
Plasmid(s) + T cells % CAT Fold
(ratioa)b activityc activationd
HIV-CAT
+ None 1.0 ± 0.4
+ Uninfected (10:1) 0.7 ± 0.2
+ Infected (10:1) 23.3 ± 2.4 33
+ Uninfected (5:1) 1.3 ± 0.4
+ Infected (5:1) 59.0 ± 6 45
+ Uninfected (2:1) 1.0 ± 0.3
+ Infected (2:1) 66.0 ± 5 66
+ Uninfected (1:1) 1.4 ± 0.3
+ Infected (1:1) 83.0 ± 6 59
+ 5 X 104 TCID50e 52.0 ± 9 52
HIV-CAT + RSV-tat
+ None 24.0 ± 2 24
+ Uninfected (2:1) 19.5 ± 4 20
+ Infected (2-1) 75.0 ± 5 3.6f
+ 5 x104TCID50 45.0 ± 4 2f
a Number of transfected cells: number of HHV-6-infected HuT-78 cells.
b HIV-CAT-transfected HuT-78 cells were cocultured in the presence of
HHV-6-infected cells or supernatant culture fluid that contained HHV-6.C CAT enzymatic activities were derived from data obtained from 3-h
reactions. Percent conversion was calculated by dividing the radioactivity
(counts per minute) present in the acetylated chloramphenicol spot by the
total radioactivity present in both the acetylated and unacetylated chloram-
phenicol spots on thin-layer chromatography. Percent CAT activity for no
plasmid was 0.05 ± 0.
d Fold activation is calculated as the increase in CAT activity over the
appropriate background levels, which are for HIV-CAT alone or HIV-CAT
with uninfected cells.
eTCID50, 50% Tissue culture infective dose.
f Fold activation is calculated as the increase in CAT activity over the
activity from HIV-CAT and RSV-tat with or without uninfected HuT cells.
cells were cotransfected with HIV-CAT and RSV-tat, a
plasmid that used the RSV promoter region to express the
tat gene (Mira Jung, personal communication). The results
showed that the HIV promoter region was consistently
responsive to trans-activation with tat by increasing CAT
activity at least 24-fold (Table 1). Although other reports
have shown higher trans-activation of the HIV-LTR, 24-fold
activation was consistently observed in these T cells, possi-
bly because of the differences in transfection procedures and
tat constructs that were used. Cells transfected with HIV-
CAT and RSV-tat which were then infected with HHV-6
showed a further 3.6-fold stimulation above that of cells
induced by tat alone (Table 1). However, when compared
with the results of previous experiments using the HIV-CAT
plasmid alone and then infection with HHV-6, the increase
in the activation of the HIV promoter is only slight. This may
be due to experimental variation or may reflect the lack of
additional activation by tat in the presence of HHV-6. These
results nevertheless suggest that HHV-6 does not compete
with tat in order to trans-activate the HIV promoter but will
increase promoter activity even when tat is present. How-
ever, it cannot be determined whether there is an additive or
cooperative effect between tat and HHV-6 on the HIV
promoter.
The results presented here are similar to those of other
studies that have demonstrated the trans-activation of HIV-
LTR by heterologous viruses (2, 10, 13). These studies have
shown that several immediate-early genes of herpes simplex
virus-1 (10), and human cytomegalovirus (2), as well as early
products from adenovirus (13), will trans-activate the HIV
promoter. This suggests that infection by HHV-6 or other
viruses may be playing an important role in converting a
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latent HIV infection to an acute phase. The molecular events
that lead to this conversion may simply be the trans-
activation of the HIV promoter, which in turn stimulates
HIV viral replication. This preliminary study does not iden-
tify the HHV-6 viral products responsible for inducing the
trans-activation of HIV; however, from the previous studies
it would likely involve early gene expression. The DNA of
HHV-6 is estimated to be more than 150 kilobases (15), and
further studies are under way to identify the HHV-6 genes
and characterize the proteins involved or required for the
trans-activation of the HIV promoter.
The mechanisms involved in the trans-activation of HIV-
LTR by other viruses is not fully understood but may
involve direct interactions of viral gene products with HIV
promoter or indirectly via cellular intermediates. A number
of cellular factors have been identified and have been shown
to bind to defined sequences of the HIV promoter region (6,
11). It is not known whether any of these factors can be
stimulated by HHV-6 infection. Examination of various
deletion mutants of the HIV-LTR region would also help to
determine which sequences are necessary for trans-activa-
tion by HHV-6. A comparison of the HHV-6 target se-
quences on the HIV-LTR promoter with the HIV sequences
known to be required by other viruses and cellular factors
would allow for the examination of common features re-
quired by several viruses for trans-activation. If these se-
quences are also known to be regions in which cellular
factors, such as Spl and NF-kB, will bind, it may indicate a
cooperation between viral proteins and cellular factors.
HHV-6 has been isolated from infants, which suggests that
infections occur early in life (19). Isolation from patients
with AIDS could merely be due to reactivation of latent
HHV-6 under immunosuppressed conditions. However, the
similarity of target cells for HHV-6 to those for HIV and our
present data suggest that HHV-6 may play a role in the
pathogenesis of HIV infection and AIDS. Moreover, HHV-6
is extremely cytolytic for human T cells in vitro (1, 8, 15, 19),
and reactivation in individuals with HIV infection could also
contribute to the depletion of T cells. Further work is in
progress to determine any possible interactions between
these two viruses.
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